

Gynecology Oncology (GynOnc) Disease-Oriented Team

Clinical Research Treatment Trial Flowchart

METASTATIC/ UNRESECTABLE

UCI 22-42

TransCon Toll like receptor (TLR) 7/8
agonist
Coord: Jiana Ejbara
Accrual: 0/5

UCI 20-110

TAK-981 (small molecule inhibitor
of SUMOylation) + Pembrolizumab
Coord: Jiana Ejbara
Accrual: 2/5

MUTATIONS

UCI 22-78

KSQ-4279 +/- Olaparib or Carboplatin
Targeting deleterious mutation (germline
or somatic)
Coord: Jiana Ejbara
Accrual:

UCI 22-77

AMG794 half-life extended (HLE) BiTE
molecule targeting CLDN6
Coord: Jiana Ejbara
Accrual: 1/8

PLATINUM-RESISTANT RECURRENCE

<4L

GOG-3066

Zn-c3

Coord: Jiana Ejbara

Accrual: 0/5

>3L

GOG-3076

Platinum Doublet + Bevacizumab +/-OlviVec

Coord: Jiana Ejbara

Accrual:

PLATINUM-SENSITIVE RECURRENCE

FRa + and >1L

GOG-3078

Mirvetuximab Soravtansine

Coord: Jiana Ejbara

Accrual: 0/5

SQUAMOUS CELL CARCINOMA

NRG-GY024

Cisplatin + Radiotherapy

Coord: Jiana Ejbara

Accrual: 0/5

TUMOR MUTATION SPECIFIC

GOG- 3083

Targeting P53 Wild-type
SELINEXOR
Coord: Jiana Ejbara
Accrual: 0/5

UTERINE SEROUS

UCI 20-203

WEE1 inhibition
Coord: Jiana Ejbara
Accrual: 0/5

ADVANCED/ METASTATIC SOLID TUMOR

UCI 22-80

Topical Pirenzepine/Placebo

Coord: Jiana Ejbara

Accrual: 1/15

OVARIAN CANCER

UCI 21-190

Assessing the Predictive Capability of Circulating Tumor DNA as a Screening Tool for Ovarian Cancer ctDNA

Coord: Jiana Ejbara

Accrual: 0/36

UCI 22-40

VIRGO2

Coord: Jiana Ejbara

Accrual:

UCI 18-120

N-Acetyl-Cysteine (NAC)

Coord: Jiana Ejbara

Accrual:

UCI 22-62

Tumor Associated Carbohydrate Antigens

Coord: Dr. Liu

Accrual: